<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360226</url>
  </required_header>
  <id_info>
    <org_study_id>REG-RES1801</org_study_id>
    <nct_id>NCT04360226</nct_id>
  </id_info>
  <brief_title>Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations</brief_title>
  <official_title>Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respiratory Effectiveness Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Respiratory Effectiveness Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, mulitcentre, observational, prospective study into Peak Inspiratory&#xD;
      Flow in COPD patients that aims to: A) Determine the prevalence of suboptimal Peak&#xD;
      Inspiratory Flow (PIF) and inadequate inhaler choice and assess the baseline characteristics&#xD;
      of these groups. B) Assess the clinical role of PIF and inhaler choice in predicting COPD&#xD;
      exacerbations and symptom burden. C) Assess the variability and correlation of PIF with other&#xD;
      lung function measurements and CAT score in stable COPD. It is a 12 month study comprising&#xD;
      one baseline assessment and 2 follow-up visits at 6 and 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of suboptimal PIF and inadequate inhaler choice.</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine the prevalence of suboptimal PIF and inadequate inhaler choice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first exacerbation associated with different levels of PIF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PIF and symptom burden</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
    <description>PIF measurements will be correlated with COPD Assessment Test (CAT) Scores. CAT scores range from 0-40 depending on the severity of a persons symptoms; higher scores denote a more severe impact of COPD on a patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Annual mortality rate associated with different PIF levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability and correlation of PIF</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
    <description>Variability of PIF over time and the correlation between PIF and other lung function measures (including FEV1, FVC, Inspiratory capacity), CAT scores, T2 markers (nasal polyps and dermatitis) and where available blood biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation rate</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Annual rate of exacerbations associated with different PIF levels</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients, who are clinically stable (4 exacerbations in previous 4 weeks) and have&#xD;
        been taking inhaled medications for at least 6 months, but have no other chronic&#xD;
        respiratory conditions, other than asthma or bronchiectasis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Spirometry-defined COPD (i.e. post-bronchodilator FEV1/FVC&lt;0.7)&#xD;
&#xD;
          2. Age â‰¥40 years&#xD;
&#xD;
          3. Smokers or ex-smokers of at least 10 pack-years&#xD;
&#xD;
          4. Clinically stable COPD (no exacerbations in the last 4 weeks)&#xD;
&#xD;
          5. Capable of performing serial lung function tests&#xD;
&#xD;
          6. Prescribed inhaled medication for at least 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Occurrence of an COPD exacerbation during the previous 4 weeks&#xD;
&#xD;
          2. Have any concomitant chronic respiratory condition other than asthma or bronchiectasis&#xD;
             (e.g. cystic fibrosis, lung fibrosis, tuberculosis)&#xD;
&#xD;
          3. Are unable to understand the instructions of the study or to fill the questionnaires&#xD;
&#xD;
          4. Are unwilling to sign the informed consent&#xD;
&#xD;
          5. Are participating in a clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Usmani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart and Lung Institute, Imperial College London &amp; Royal Brompton Hosp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omar Usmani, MD</last_name>
    <phone>+44 (0)20 7351 8051</phone>
    <email>o.usmani@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Lucas, PhD</last_name>
    <email>sarah@REGresearchnetwork.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Sassari</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pietro Pirina, MD</last_name>
      <email>pirina@uniss.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin Kook Rhee, MD</last_name>
      <email>chinkook77@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chin Kook Rhee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Dei Hospital</name>
      <address>
        <city>Valletta</city>
        <country>Malta</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Gouder, MD</last_name>
      <email>carolinegouder@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Caroline Gouder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Loh Chee Hong, MD</last_name>
      <email>loh.chee.hong@singhealth.com.sg</email>
    </contact>
    <investigator>
      <last_name>Sean Loh Chee Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei Yee Tiew, MD</last_name>
      <email>tiew.pei.yee@singhealth.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ljubljana University Medical Centre</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matevz Harlander, MD</last_name>
      <email>matevz.harlander@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Miravitlles, MD</last_name>
      <email>marcm@separ.es</email>
    </contact>
    <investigator>
      <last_name>Marc Miravitlles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Inmaculada HLA</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Romero, MD</last_name>
      <email>pjromerop@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HU Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernardino Alcazar Navarrete, MD</last_name>
      <email>balcazarnavarrete@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Ribera</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Navals, MD</last_name>
      <email>elsa.navals@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malta</country>
    <country>Singapore</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

